| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/23/2004 | EP1430057A2 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives |
| 06/23/2004 | EP1430056A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders |
| 06/23/2004 | EP1430055A1 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine for the treatment of anxiety and convulsions |
| 06/23/2004 | EP1430053A1 Chemical compounds |
| 06/23/2004 | EP1430051A1 N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamines as antiproliferative compounds |
| 06/23/2004 | EP1430050A1 Piperidine derivatives and their use as modulators of chemokine (especially ccr3) activity |
| 06/23/2004 | EP1430048A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| 06/23/2004 | EP1430047A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 06/23/2004 | EP1430046A1 Process for preparing pyridyl-alkylsulfonyl pyrazole derivatives |
| 06/23/2004 | EP1430044A1 Process for the preparation of citalopram |
| 06/23/2004 | EP1430043A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists |
| 06/23/2004 | EP1430042A2 Bicyclic heterocycles as rxr ligands |
| 06/23/2004 | EP1430041A2 Novel sulfonic acid derivatives |
| 06/23/2004 | EP1430040A1 Benzothiazepine derivatives |
| 06/23/2004 | EP1430039A2 Aryl derivatives for the treatment of diabetes, hyperlipidemia, hypercholesterolemia and atherosclerosis |
| 06/23/2004 | EP1430034A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
| 06/23/2004 | EP1430033A1 Anti-inflammatory and protein kinase inhibitor composition and method of use |
| 06/23/2004 | EP1430032A2 Substituted amides for the treatment of neurological disorders |
| 06/23/2004 | EP1430031A2 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 06/23/2004 | EP1430030A1 N-type calcium channel antagonists for the treatment of pain |
| 06/23/2004 | EP1430029A1 N-type calcium channel antagonists for the treatment of pain |
| 06/23/2004 | EP1430027A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| 06/23/2004 | EP1430026A1 3-desoxy-vitamin d3 analog esters |
| 06/23/2004 | EP1430025A1 Methods and compositions for treating or preventing bacterial infection |
| 06/23/2004 | EP1430024A1 Alkyl urea retinoid agonists i |
| 06/23/2004 | EP1430023A1 Substituied urea retinoid agonists ii |
| 06/23/2004 | EP1430020A1 Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them |
| 06/23/2004 | EP1430019A1 Sphingolipids |
| 06/23/2004 | EP1430017A2 Substituted phenol compounds useful for anesthesia and sedation |
| 06/23/2004 | EP1429915A1 Systems, methods and apparatuses for manufacturing dosage forms |
| 06/23/2004 | EP1429914A1 Systems, method and apparatuses for manufacturing dosage forms |
| 06/23/2004 | EP1429845A2 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 06/23/2004 | EP1429844A2 Conjugated anti-psychotic drugs and uses thereof |
| 06/23/2004 | EP1429843A2 Combination of a pde inhibitor and a leukotriene receptor antagonist |
| 06/23/2004 | EP1429819A1 Optimized dosing for drug coated stents |
| 06/23/2004 | EP1429817A1 Porous ceramic composite bone grafts |
| 06/23/2004 | EP1429815A1 Mixture for use as a protective dressing |
| 06/23/2004 | EP1429811A1 Theurapeutic tropane compounds |
| 06/23/2004 | EP1429807A2 Combination of a nsaid and a pde-4 inhibitor |
| 06/23/2004 | EP1429800A2 Vaccine and method for treatment of motor neurone diseases |
| 06/23/2004 | EP1429798A1 Optimal compositions and methods thereof for treating hcv infections |
| 06/23/2004 | EP1429797A2 Diagnosis and treatment of malignant neoplasms |
| 06/23/2004 | EP1429791A2 Method and topical formulation for treating skin conditions associated with aging |
| 06/23/2004 | EP1429789A2 Anti-infectious carbohydrates |
| 06/23/2004 | EP1429788A2 Use of mannosamine derivatives for the stimulation of neurite growth |
| 06/23/2004 | EP1429787A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder |
| 06/23/2004 | EP1429786A1 D-mannose contraceptives |
| 06/23/2004 | EP1429783A2 Multi-use multimodal imaging chelates |
| 06/23/2004 | EP1429782A1 Modulation of vitamin storage |
| 06/23/2004 | EP1429781A2 Composition comprising nanoparticulate spironolactone |
| 06/23/2004 | EP1429780A1 Method of treating middle ear infections |
| 06/23/2004 | EP1429779A2 Androstanes as androgen receptor modulators |
| 06/23/2004 | EP1429778A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents |
| 06/23/2004 | EP1429777A1 Ophthalmologic treatment methods using selective inos inhibitors |
| 06/23/2004 | EP1429776A2 Tricyclic indole derivatives as 5-ht ligands |
| 06/23/2004 | EP1429775A1 Methods of treating pulmonary disease |
| 06/23/2004 | EP1429774A2 Stent coated with a substained-release drug delivery |
| 06/23/2004 | EP1429773A1 Process for making substituted pyrazoles |
| 06/23/2004 | EP1429772A1 N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole |
| 06/23/2004 | EP1429771A2 Bicyclic compounds as inhibitors of chemokine binding to us28 |
| 06/23/2004 | EP1429770A1 New formulations and use thereof |
| 06/23/2004 | EP1429769A1 New formulations and use thereof |
| 06/23/2004 | EP1429768A1 Novel medicaments for inhalation |
| 06/23/2004 | EP1429767A1 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
| 06/23/2004 | EP1429766A1 Pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| 06/23/2004 | EP1429765A2 Inhibitors of histone deacetylase |
| 06/23/2004 | EP1429764A1 Compositions and methods for the treatment of cancer |
| 06/23/2004 | EP1429763A2 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
| 06/23/2004 | EP1429762A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity |
| 06/23/2004 | EP1429761A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 06/23/2004 | EP1429760A1 Novel combination |
| 06/23/2004 | EP1429758A1 Photodynamic porphyrin antimicrobial agents |
| 06/23/2004 | EP1429757A2 Crystalline forms of fluvastatin sodium |
| 06/23/2004 | EP1429756A2 Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| 06/23/2004 | EP1429755A1 Use of vitamin e succinate and antiandrogen combination |
| 06/23/2004 | EP1429754A1 Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
| 06/23/2004 | EP1429753A1 Pharmaceutical composition comprising gamma-butyrobetaine |
| 06/23/2004 | EP1429752A1 Neuroprotective treatment methods using selective inos inhibitors |
| 06/23/2004 | EP1429751A1 Salicylic acid salts, methods for the production and use thereof as medicaments |
| 06/23/2004 | EP1429750A2 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto |
| 06/23/2004 | EP1429749A2 Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| 06/23/2004 | EP1429748A1 Solid compositions comprising ramipril |
| 06/23/2004 | EP1429747A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 06/23/2004 | EP1429746A2 Dosage forms having an inner core and outer shell |
| 06/23/2004 | EP1429745A2 Composite dosage forms having an inlaid portion |
| 06/23/2004 | EP1429743A1 Dosage forms having an inner core and outer shell with different shapes |
| 06/23/2004 | EP1429742A2 Modified release dosage forms |
| 06/23/2004 | EP1429740A1 Core formulation comprising troglitazone and a biguanide |
| 06/23/2004 | EP1429738A2 Modified release dosage forms |
| 06/23/2004 | EP1429737A1 Modified release dosage forms |
| 06/23/2004 | EP1429736A2 Organoleptically acceptable intraorally disintegrating compositions |
| 06/23/2004 | EP1429734A1 Controlled release solid dispersions |
| 06/23/2004 | EP1429732A1 A core formulation |
| 06/23/2004 | EP1429730A2 Opioid formulations having reduced potential for abuse |
| 06/23/2004 | EP1429729A1 Combination dosage form containing a cholesterol -lowering agent , an inhibitor of the renin-angiotensin, and aspirin |
| 06/23/2004 | EP1429728A1 Sustained release preparations |
| 06/23/2004 | EP1429727A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment |
| 06/23/2004 | EP1429725A1 Ophthalmic depot formulations for periocular or subconjunctival administration |
| 06/23/2004 | EP1429724A1 Dosage form containing a confectionery composition |
| 06/23/2004 | EP1429723A1 Treating effects of excessive reactive oxygen species |